These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8731957)

  • 1. Experimental studies on preventive effects of API0134 on vessel reocclusion after thrombolysis.
    Xiong YL; Zhao HY
    J Tongji Med Univ; 1995; 15(2):77-81. PubMed ID: 8731957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y; Asai F; Wada K; Nakashima M
    Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis.
    Werns SW; Rote WE; Davis JH; Guevara T; Lucchesi BR
    Am Heart J; 1994 Apr; 127(4 Pt 1):727-37. PubMed ID: 8154409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H
    Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
    Curl GR; Jakubowski JA; Deykin D; Bush HL
    Circulation; 1986 Sep; 74(3 Pt 2):I21-4. PubMed ID: 3091289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats.
    Deng ZY; Shan WG; Wang SF; Hu MM; Chen Y
    Pharm Biol; 2017 Dec; 55(1):663-672. PubMed ID: 27951728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator.
    Yamada Y; Furui H; Furumichi T; Yamauchi K; Yokota M; Saito H
    Am Heart J; 1991 Jun; 121(6 Pt 1):1618-27. PubMed ID: 1903579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
    Haskel EJ; Adams SP; Feigen LP; Saffitz JE; Gorczynski RJ; Sobel BE; Abendschein DR
    Circulation; 1989 Dec; 80(6):1775-82. PubMed ID: 2513145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
    Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
    Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic effects of Andrographis paniculata nees in preventing myocardial infarction.
    Zhao HY; Fang WY
    Chin Med J (Engl); 1991 Sep; 104(9):770-5. PubMed ID: 1935360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of berberine on synthesis of platelet TXA2 and plasma PGI2 in rabbits].
    Huang CG; Chu ZL; Yang ZM
    Zhongguo Yao Li Xue Bao; 1991 Nov; 12(6):526-8. PubMed ID: 1824005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
    Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
    Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
    Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
    Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
    Fitzgerald DJ; Wright F; FitzGerald GA
    Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.